Neuroblastoma Market size was over USD 3.03 Billion in 2023 and is projected to cross USD 5.37 Billion by the end of 2036, witnessing more than 4.5% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of neuroblastoma is estimated at USD 3.15 Billion. The growth of the market can be attributed to the increasing incidence of neuroblastoma and the development of new and advanced treatment methods. For instance, neuroblastoma accounts for approximately 8–10% of all cases of childhood cancer. According to statistics, neuroblastoma occurs in 11 to 13 children under the age of 15 per million, and in children 10–14 years of age, the incidence rate rises to 65 per million. Neuroblastoma is a type of cancer that affects the peripheral nervous system, which is made up of nerves that connect the central nervous system to the rest of the body. As this type of cancer becomes more common, the need for diagnosis, treatment, and management of the disease is expected to increase, thereby driving the growth of the neuroblastoma market.
In addition to these, factors that are believed to fuel the market growth of neuroblastoma include increasing investments in the healthcare sector, the rising number of clinical trials, and the growing awareness about the disease among patients. Furthermore, an increasing success rate for cancer immunotherapy is further projected to enhance market growth. For instance, it has been estimated that 87% of children in the UK who have successfully completed immunotherapy have shown no evidence of disease last two years after completing the treatment. Also, five years after immunotherapy begins, approximately 78% of children in remission remain free of disease. The success rate of immunotherapy has been increasing owing to advancements in cancer research and the development of new drugs, which can help to improve the chances of survival for patients with neuroblastoma.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
4.5% |
|
Base Year Market Size (2023) |
USD 3.03 Billion |
|
Forecast Year Market Size (2036) |
USD 5.37 Billion |
|
Regional Scope |
|
Treatment Type (Chemotherapy, Immunotherapy)
The global neuroblastoma market is segmented and analyzed for demand and supply by treatment type into chemotherapy, immunotherapy, and others. Out of these, the chemotherapy segment is estimated to gain the largest market share of about 37% in the year 2036. The growth of the segment can be attributed to the rising investments in research and development activities for the development of new chemotherapeutic drugs. Furthermore, the increasing number of clinical trials for the development of advanced chemotherapeutic agents is further expected to fuel the growth of the segment. For instance, a variety of advanced therapeutic agents are being developed, including alkylating agents, antimetabolites, antimicrotubular agents, as well as antibiotics like actinomycin D, bleomycin, and daunomycin. Additionally, chemotherapy has been the mainstay of treatment for neuroblastoma and is expected to remain so in the near future.
Product Type (Tablets, Vaccines)
The global neuroblastoma market is segmented and analyzed for demand and supply by product type into tablets, vaccines, and others. Out of these, the tablets segment is estimated to gain a significant market share of about 39% in the year 2036. The tablets segment has seen tremendous growth owing to the ease of administration, better efficacy and safety profiles, and increased affordability compared to other product types. Furthermore, the emergence of precision medicine has also contributed to the growth of this segment as it is able to provide personalized drug therapies tailored to individual patients’ needs. Tablet dosage forms have higher bioavailability, meaning that more of the active ingredients are absorbed into the bloodstream, thus providing more effective treatments with fewer side effects. Additionally, tablets are easy to store, handle, and transport, making them more cost-effective than other forms of product.
Our in-depth analysis of the global market includes the following segments:
|
By Treatment Type |
|
|
By Product Type |
|
|
By Distribution Channel |
|
|
By End User |
|
North American Market Forecast
The market share of neuroblastoma in North America, amongst the market in all the other regions, is projected to be the largest with a share of about 37% by the end of 2036. The growth of the market can be attributed majorly to the rising prevalence of neuroblastoma cancer, increasing healthcare expenditure, and the rising number of hospitals in the region. It is believed that neuroblastoma poses the greatest threat to infants (under a year of age). The American Cancer Society estimates that there are 700 to 800 new cases of neuroblastoma each year in the United States. Additionally, the region's increasing awareness of effective treatments and the availability of advanced diagnostic imaging techniques and targeted therapies are contributing to the market's growth. This increased access to diagnostic imaging has improved efficiency and accuracy of disease diagnosis, which has ultimately led to improved patient outcomes and better quality of care.
APAC Market Statistics
The Asia Pacific neuroblastoma market is estimated to be the second largest, registering a share of about 27% by the end of 2036. The growth of the market can be attributed majorly to the growing awareness about the disease, increasing demand for advanced treatments, and the presence of numerous biopharmaceutical companies in the region. Furthermore, the increasing focus on research & development activities in the region is also expected to aid the growth of the neuroblastoma market. The increased healthcare infrastructure and public support allows for more accessible healthcare, which leads to higher life expectancies and better quality of life. Additionally, government initiatives and investments designed to increase access to healthcare are also contributing factors. These include initiatives to expand healthcare coverage to rural and low-income communities, as well as initiatives to increase the number of healthcare professionals working in the region.
Europe Market Forecast
Further, the neuroblastoma market in Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2036. The growth of the market can be attributed majorly to the rising prevalence of the disease, increasing initiatives by the government to promote research and development, and the increasing availability of advanced diagnostic technologies. According to the research, there are approximately 100 children in the UK who are affected by Neuroblastoma each year. Additionally, the government has been introducing various initiatives and programs to increase research and development activities in this field in order to find better treatments for the disease. Furthermore, the increasing availability of advanced diagnostic technologies has enabled earlier and more accurate diagnosis of this disease. This has also contributed to the growth of the market.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?